Avita Medical

Avita Medical

Update 11/8: Reported record 2Q26 revenue of US$21.7m (+18% YoY, +13% QoQ), driven by US RECELL unit volume growth and contributions from Cohealyx and PermeaDerm. Management upgraded FY26 revenue guidance to US$86-89m and anticipates cash-flow breakeven in 4Q26.

You’re not a member!  Trial today

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.